Promotive Communications

Laboratory Focus January 2010

Laboratory Focus is Canada's leading editorial-based lab publication. Providing readers with the latest technology updates through application and tech notes, as well as covering new products and trends in laboratories across Canada.

Issue link: http://laboratoryfocus.uberflip.com/i/111845

Contents of this Issue

Navigation

Page 0 of 19

P h ar m ace u tical C linical C h e m ical f ood w w w. b i o s c i e n c e w o r l d . c a Cell Culture CO2 Incubator Technical Report Page 8 JANUARY 2010 Volume 14, Number 1 Efficient Genomic DNA Extraction from Low Target Concentration E. coli Cultures using SCODA DNA Extraction Technology Page 12 MaRS Innovation and CDRD announce strategic collaboration tion. ���By entering into this innovative agreement, we believe the commercial potential of select projects in our pipeline will be enhanced,��� he said. The first joint project arising out of this collaboration involves technology developed by Dr. Paul Fraser (University of Toronto) and Dr. Bruce Verchere (University of British Columbia), who together are investigating amyloid aggregation inhibitors as a novel approach to address the treatment of diabetes. ���As the inventor, I am looking forward to seeing this innovative technology progress even further by combining the extensive medicinal chemistry work of my lab with the diabetes-specific expertise of Dr. Verchere. The support of MI and CDRD will accelerate and augment the development of this program,��� MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize earlystage health-related discoveries. ���We are excited about our partnership with the CDRD as it provides an Publications Mail Registration Number: 40052410 opportunity for the two organizations to augment each other���s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations��� mandates of commercializing promising academicresearch,��� said Dr. Rafi Hofstein, president and CEO of MaRS Innova- en v iron m ent R&D News.......................... 1 Pharma Notes. ................... 6 . Appointments..................... 7 New Products................... 14 Calendar........................... 17 Career Spotlight............... 18 said Dr. Fraser, professor and Diener chair for Neurodegenerative Diseases at the University of Toronto. ���We believe this technology has the potential to be disease modifying and could create a new paradigm for treating Type 2 Diabetes. This partnership allows us to leverage resources and still focus on our core interests and capabilities. Working with MI and CDRD will provide us with project management oversight, funding support, and access to extensive drug development personnel and infrastructure,��� said Dr. Verchere, professor and Irving K Barber chair in Diabetes Research at the University of British Columbia. Dr. Verchere is also head of the Diabetes Research Program at the Child & Family Research Institute (CFRI). The Government of Canada���s Networks of Centres of Excellence program has recognized both MaRS Innovation and CDRD as ���Centres of Excellence in Commercialization in Research (CECR)���. Two highest doses removed from AD251 Phase II trial, lowest dose continues as planned Elan Corporation, plc and Transition Therapeutics, Inc. have notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer���s disease. The AD201 study is evaluating three dose levels of ELND005 compared to placebo in 353 patients. Patients will be withdrawn immediately from the study in the two higher dose groups (1000mg and 2000mg dosed twice daily). The study will continue unchanged for patients who are assigned to the lower dose (250mg dosed twice daily) and placebo groups. The AD251 study will be modified to dose patients only at 250mg twice daily. The decision by the companies to take these actions was made in concurrence with the Independent Safety Monitoring Committee (ISMC) following a review of the ongoing ELND005-AD201 study. Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses. A direct relationship between ELND005 and these deaths has not been established.

Articles in this issue

Links on this page

view archives of Promotive Communications - Laboratory Focus January 2010